MSB 2.17% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-316

  1. 12,336 Posts.
    lightbulb Created with Sketch. 180
    Picked up o the global newswire Xinhua
    - from Nigeria

    https://nnn.com.ng/stem-cell-drug-shows-promise-for-ventilator-dependent-covid-19-patients/


    FOREIGN

    Stem cell drug shows promise for ventilator-dependent COVID-19 patients



    An Australian drug manufacturer has claimed success treating COVID-19 patients who were dependent on ventilators, revealing that seven out of 12 seriously ill patients were discharged from hospital after receiving an experimental stem cell produt

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.